Vitamin D Receptor Genetic Polymorphisms and Prostate Cancer Risk: A Meta-analysis of 36 Published Studies.
To update data on the role of vitamin D receptor (VDR) single nucleotide polymorphisms (SNPs) in susceptibility to prostate cancer, we performed a meta-analysis of 36 eligible publications on the association of Taql, Apal, Bsml, Fokl and CDX2 SNPs of the VDR gene with prostate cancer risk. Our study suggested that the Taql t and Bsml B alleles were associated with reduced prostate cancer risk among all study populations. Stratified analysis by ethnicity revealed that the Apal a allele was associated with reduced prostate cancer risk only among Asian populations, whereas the Fokl f allele showed a trend of increased prostate cancer risk only among Caucasian populations in a dominant model, independent of tumor stage (local or advanced). These results suggest that VDR polymorphisms may be potential biomarkers for prostate cancer susceptibility.
Yin
Ming
M
Departments of Epidemiology, The University of Texas, M. D. Anderson Cancer Center 1515 Holcombe Blvd, Houston, TX77030, USA.
Wei
Sheng
S
Wei
Qingyi
Q
Urol Clin North Am. 2003 May;30(2):209-17
12735498
Eur Urol. 2000 Feb;37(2):234-8
10705205
Asian Pac J Cancer Prev. 2006 Jan-Mar;7(1):136-9
16629532
Exp Biol Med (Maywood). 2008 Dec;233(12):1608-14
18849534
J Bone Miner Res. 1996 Dec;11(12):1850-5
8970885
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1990-9
17932346
Urol Int. 2002;68(4):226-31
12053022
J Urol. 2006 May;175(5):1613-23
16600714
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Oncogene. 2000 Oct 19;19(44):5091-7
11042697
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):997-9
15824177
Carcinogenesis. 2001 Sep;22(9):1343-7
11532853
Int J Biol Markers. 2004 Jul-Sep;19(3):245-9
15503828
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Ann Intern Med. 1997 Nov 1;127(9):820-6
9382404
PLoS Med. 2007 Mar;4(3):e103
17388667
Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):467-72
8220092
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):221-5
15225775
Mol Cell Endocrinol. 2001 May 25;177(1-2):145-59
11377830
Cancer Lett. 2004 Apr 15;207(1):69-77
15050735
Cancer Res. 2000 Jan 15;60(2):305-8
10667581
Saudi Med J. 2004 Apr;25(4):447-51
15083213
Oncology. 2006;71(1-2):111-23
17377416
Eur J Cancer. 2009 Mar;45(4):634-41
19008093
Am J Clin Nutr. 2008 Aug;88(2):565S-569S
18689403
Biometrics. 2000 Jun;56(2):455-63
10877304
Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):385-90
9610787
Mol Endocrinol. 1997 Jul;11(8):1165-79
9212063
J Urol. 1998 Oct;160(4):1405-9
9751364
Cancer Res. 2005 Jun 15;65(12):5470-9
15958597
Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1429-37
14693733
BMJ. 1997 Sep 13;315(7109):629-34
9310563
N Engl J Med. 1992 Jul 23;327(4):248-54
1614465
J Natl Cancer Inst. 2008 Jun 4;100(11):796-804
18505967
Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2549-52
17164384
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10529-34
9724737
Cancer Res. 1992 Feb 1;52(3):515-20
1370648
Nature. 1994 Jan 20;367(6460):284-7
8161378
Endocrinology. 1993 May;132(5):1952-60
7682937
Endocr J. 1999 Jun;46(3):467-70
10504001
Int J Urol. 2003 May;10(5):261-6
12694466
Cancer. 1992 Dec 15;70(12):2861-9
1451068
Prostate. 2007 Jun 15;67(9):911-23
17440943
Mol Carcinog. 2000 Jan;27(1):18-23
10642433
Cancer Res. 1994 Feb 1;54(3):805-10
7508338
Clin Cancer Res. 2008 May 15;14(10):3223-9
18483391
J Bone Miner Res. 1998 Nov;13(11):1691-9
9797477
Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1395-402
14693728
J Biol Chem. 2004 Apr 16;279(16):16754-66
14739296
Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1325-30
15298953
Anticancer Res. 1999 Sep-Oct;19(5C):4511-4
10650802
Acta Oncol. 2005;44(3):277-81
16076700
Hum Genet. 1999 Sep;105(3):281-7
10987658
Prostate. 2004 Jun 1;59(4):409-18
15065089
Urology. 2001 Mar;57(3):567-72
11248649
Cancer Res. 1998 Apr 15;58(8):1620-3
9563471
J Bone Miner Res. 2001 Jul;16(7):1256-64
11450701